| Trial ID: | L1848 |
| Source ID: | NCT00600366
|
| Associated Drug: |
Biphasic Insulin Aspart
|
| Title: |
Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart
|
| Outcome Measures: |
Primary: HbA1c, after 12 weeks of treatment | Secondary: Blood glucose profiles|Incidence of hypoglycaemic episodes|Incidence of adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
71
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-03
|
| Completion Date: |
2005-01
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-06
|
| Locations: |
Novo Nordisk Investigational Site, Belgrade, 11000, Former Serbia and Montenegro|Novo Nordisk Investigational Site, Kragujevac, 34000, Former Serbia and Montenegro|Novo Nordisk Investigational Site, Nis, 18000, Former Serbia and Montenegro|Novo Nordisk Investigational Site, Novi Sad, 21000, Former Serbia and Montenegro
|
| URL: |
https://clinicaltrials.gov/show/NCT00600366
|
